Trial Profile
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
Status:
Not stated
Phase of Trial:
Phase IV
Latest Information Update: 23 Aug 2012
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin
- Indications Stroke; Thromboembolism
- Focus Therapeutic Use
- Acronyms RE-LY; ROCKET-AF
- 23 Aug 2012 New trial record